BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer

Gynecologic Oncology

Volumn 123, Issue 3, 2011, Pages 492-498

  Carser, Judith E ^a   Quinn, Jennifer E ^a   Michie, Caroline O ^b   O'Brien, Eamonn J ^c   McCluggage, W Glenn ^d   Maxwell, Perry ^a,d   Lamers, Elisabeth ^a   Lioe, Tong F ^e   Williams, Alistair R W ^b   Kennedy, Richard D ^a,c   Gourley, Charlie ^b   Harkin, D Paul ^a,c  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c Almac Sciences   (United Kingdom)

^d ROYAL VICTORIA HOSPITAL   (United Kingdom)

^e BELFAST CITY HOSPITAL   (United Kingdom)

Author keywords

Biomarker; BRCA1; Chemotherapy; Ovarian cancer; Predictive; Prognostic

Indexed keywords

BRCA1 PROTEIN; PLATINUM; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; EPITHELIAL OVARIAN CANCER; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRCA1 PROTEIN; BRIDGED COMPOUNDS; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS, GLANDULAR AND EPITHELIAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAXOIDS; TUMOR MARKERS, BIOLOGICAL;

EID: 81155133676     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.08.017     Document Type: Article

References (41)

1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M.J. Thun Cancer statistics, 2009 CA Cancer J Clin 59 2009 225 249
2. Cancer research UK Ovarian cancer statistics - key facts 2008 http://info.cancerresearchuk.org/cancerstats/types/ovary/#Ovarian
3. W.P. McGuire, W.J. Hoskins, M.F. Brady, P.R. Kucera, E.E. Partridge, and K.Y. Look Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med 334 1996 1 6 (Pubitemid 26012496)
4. M.J. Piccart, K. Bertelsen, K. James, J. Cassidy, C. Mangioni, and E. Simonsen Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results J Natl Cancer Inst 92 2000 699 708 (Pubitemid 30365530)
5. A. du Bois, M. Quinn, T. Thigpen, J. Vermorken, E. Avall-Lundqvist, and M. Bookman 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004) Ann Oncol 16 Suppl 8 2005 viii7 viii12
6. F.M. Muggia, P.S. Braly, M.F. Brady, G. Sutton, T.H. Niemann, and S.L. Lentz Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study J Clin Oncol 18 2000 106 115 (Pubitemid 30036343)
7. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial Lancet 360 2002 505 515
8. T. Pal, J. Permuth-Wey, J.A. Betts, J.P. Krischer, J. Fiorica, and H. Arango BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases Cancer 104 2005 2807 2816 (Pubitemid 41798292)
9. M.L. McCoy, C.R. Mueller, and C.D. Roskelley The role of the breast cancer susceptibility gene 1 (BRCA1) in sporadic epithelial ovarian cancer Reprod Biol Endocrinol 1 2003 72
10. J.P. Geisler, M.A. Hatterman-Zogg, J.A. Rathe, and R.E. Buller Frequency of BRCA1 dysfunction in ovarian cancer J Natl Cancer Inst 94 2002 61 67 (Pubitemid 34082844)
11. C. Wang, A. Horiuchi, T. Imai, S. Ohira, K. Itoh, and T. Nikaido Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene J Pathol 202 2004 215 223 (Pubitemid 38208659)
12. E.M. Swisher, R.M. Gonzalez, T. Taniguchi, R.L. Garcia, T. Walsh, and B.A. Goff Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas Mol Cancer 8 2009 48
13. D.S. Tan, C. Rothermundt, K. Thomas, E. Bancroft, R. Eeles, and S. Shanley "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations J Clin Oncol 26 2008 5530 5536
14. M. Thrall, H.H. Gallion, R. Kryscio, M. Kapali, D.K. Armstrong, and J.A. DeLoia BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study Int J Gynecol Cancer 16 Suppl 1 2006 166 171
15. J.E. Quinn, C.R. James, G.E. Stewart, J.M. Mulligan, P. White, and G.K. Chang BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy Clin Cancer Res 13 2007 7413 7420
16. J. Weberpals, K. Garbuio, A. O'Brien, K. Clark-Knowles, S. Doucette, and O. Antoniouk The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer Int J Cancer 124 2009 806 815
17. T. Byrski, J. Gronwald, T. Huzarski, E. Grzybowska, M. Budryk, and M. Stawicka Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers Breast Cancer Res Treat 108 2008 289 296 (Pubitemid 351311366)
18. P.J. Wysocki, K. Korski, K. Lamperska, J. Zaluski, and A. Mackiewicz Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations Med Sci Monit 14 2008 SC7 SC10
19. C.A. Wilson, L. Ramos, M.R. Villasenor, K.H. Anders, M.F. Press, and K. Clarke Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas Nat Genet 21 1999 236 240 (Pubitemid 29070375)
20. A. Alamshah, R. Springall, C.E. Gillett, E. Solomon, and J.R. Morris Use of a BRCA1 peptide validates MS110 as a BRCA1-specific antibody in immunohistochemistry Histopathology 53 2008 117 120 (Pubitemid 351861977)
21. M.A. Bookman, M.F. Brady, W.P. McGuire, P.G. Harper, D.S. Alberts, and M. Friedlander Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup J Clin Oncol 27 2009 1419 1425
22. H. Aida, K. Takakuwa, H. Nagata, I. Tsuneki, M. Takano, and S. Tsuji Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1 Clin Cancer Res 4 1998 235 240 (Pubitemid 28062902)
23. S.C. Rubin, I. Benjamin, K. Behbakht, H. Takahashi, M.A. Morgan, and V.A. LiVolsi Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1 N Engl J Med 335 1996 1413 1416 (Pubitemid 26382501)
24. J. Boyd, Y. Sonoda, M.G. Federici, F. Bogomolniy, E. Rhei, and D.L. Maresco Clinicopathologic features of BRCA-linked and sporadic ovarian cancer Jama 283 2000 2260 2265 (Pubitemid 30246777)
25. I. Cass, R.L. Baldwin, T. Varkey, R. Moslehi, S.A. Narod, and B.Y. Karlan Improved survival in women with BRCA-associated ovarian carcinoma Cancer 97 2003 2187 2195 (Pubitemid 36444059)
26. E.J. Majdak, J. Debniak, T. Milczek, C.J. Cornelisse, P. Devilee, and J. Emerich Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma Cancer 104 2005 1004 1012 (Pubitemid 41170228)
27. A. Chetrit, G. Hirsh-Yechezkel, Y. Ben-David, F. Lubin, E. Friedman, and S. Sadetzki Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer J Clin Oncol 26 2008 20 25
28. C. Gourley, C.O. Michie, P. Roxburgh, T.A. Yap, S. Harden, and J. Paul Increased incidence of visceral metastases in Scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype J Clin Oncol 28 2010 2505 2511
29. W. Zheng, F. Luo, J.J. Lu, A. Baltayan, M.F. Press, and Z.F. Zhang Reduction of BRCA1 expression in sporadic ovarian cancer Gynecol Oncol 76 2000 294 300 (Pubitemid 30131496)
30. M.E. Robson, P.O. Chappuis, J. Satagopan, N. Wong, J. Boyd, and J.R. Goffin A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment Breast Cancer Res 6 2004 R8 R17
31. A. Husain, G. He, E.S. Venkatraman, and D.R. Spriggs BRCA1 up-regulation is associated with repair-mediated resistance to cis- diamminedichloroplatinum(II) Cancer Res 58 1998 1120 1123 (Pubitemid 28183195)
32. C. Zhou, P. Huang, and J. Liu The carboxyl-terminal of BRCA1 is required for subnuclear assembly of RAD51 after treatment with cisplatin but not ionizing radiation in human breast and ovarian cancer cells Biochem Biophys Res Commun 336 2005 952 960 (Pubitemid 41338360)
33. S. Lafarge, V. Sylvain, M. Ferrara, and Y.J. Bignon Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway Oncogene 20 2001 6597 6606 (Pubitemid 32980286)
34. D. Xing, and S. Orsulic A mouse model for the molecular characterization of brca1-associated ovarian carcinoma Cancer Res 66 2006 8949 8953 (Pubitemid 44521109)
35. K.V. Clark-Knowles, K. Garson, J. Jonkers, and B.C. Vanderhyden Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes Exp Cell Res 313 2007 133 145 (Pubitemid 44958459)
36. J.E. Quinn, J.E. Carser, C.R. James, R.D. Kennedy, and D.P. Harkin BRCA1 and implications for response to chemotherapy in ovarian cancer Gynecol Oncol 113 2009 134 142
37. J.E. Quinn, R.D. Kennedy, P.B. Mullan, P.M. Gilmore, M. Carty, and P.G. Johnston BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis Cancer Res 63 2003 6221 6228 (Pubitemid 37255167)
38. C. Chabalier, C. Lamare, C. Racca, M. Privat, A. Valette, and F. Larminat BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance Cell Cycle 5 2006 1001 1007
39. N. Katsumata, M. Yasuda, F. Takahashi, S. Isonishi, T. Jobo, and D. Aoki Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial Lancet 374 2009 1331 1338
40. M.W. Audeh, J. Carmichael, R.T. Penson, M. Friedlander, B. Powell, and K.M. Bell-McGuinn Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial Lancet 376 2010 245 251
41. P.A. Konstantinopoulos, D. Spentzos, B.Y. Karlan, T. Taniguchi, E. Fountzilas, and N. Francoeur Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer J Clin Oncol 28 2010 3555 3561